Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Computational metabolism modeling predicts risk of distant relapse-free survival in breast cancer patients.

Trilla-Fuertes L, Gámez-Pozo A, Díaz-Almirón M, Prado-Vázquez G, Zapater-Moros A, López-Vacas R, Nanni P, Zamora P, Espinosa E, Fresno Vara JÁ.

Future Oncol. 2019 Oct;15(30):3483-3490. doi: 10.2217/fon-2018-0698. Epub 2019 Oct 3.

PMID:
31580166
2.

Melanoma proteomics suggests functional differences related to mutational status.

Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, Zapater-Moros A, Díaz-Almirón M, Fortes C, Ferrer-Gómez M, López-Vacas R, Parra Blanco V, Márquez-Rodas I, Soria A, Fresno Vara JÁ, Espinosa E.

Sci Rep. 2019 May 10;9(1):7217. doi: 10.1038/s41598-019-43512-z.

3.

Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer.

Rojas L K, Trilla-Fuertes L, Gámez-Pozo A, Chiva C, Sepúlveda J, Manso L, Prado-Vázquez G, Zapater-Moros A, López-Vacas R, Ferrer-Gómez M, Mendiola C, Espinosa E, Sabidó E, Ciruelos E, Vara JÁF.

Ecancermedicalscience. 2019 Jan 15;13:891. doi: 10.3332/ecancer.2019.891. eCollection 2019.

4.

A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.

Prado-Vázquez G, Gámez-Pozo A, Trilla-Fuertes L, Arevalillo JM, Zapater-Moros A, Ferrer-Gómez M, Díaz-Almirón M, López-Vacas R, Navarro H, Maín P, Feliú J, Zamora P, Espinosa E, Fresno Vara JÁ.

Sci Rep. 2019 Feb 7;9(1):1538. doi: 10.1038/s41598-018-38364-y.

5.

Molecular characterization of breast cancer cell response to metabolic drugs.

Trilla-Fuertes L, Gámez-Pozo A, Arevalillo JM, Díaz-Almirón M, Prado-Vázquez G, Zapater-Moros A, Navarro H, Aras-López R, Dapía I, López-Vacas R, Nanni P, Llorente-Armijo S, Arias P, Borobia AM, Maín P, Feliú J, Espinosa E, Fresno Vara JÁ.

Oncotarget. 2018 Jan 8;9(11):9645-9660. doi: 10.18632/oncotarget.24047. eCollection 2018 Feb 9.

6.

Urothelial cancer proteomics provides both prognostic and functional information.

de Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sepúlveda JM, Prado-Vazquez G, Arevalillo JM, Zapater-Moros A, Navarro H, Lopez-Vacas R, Manneh R, Otero I, Villacampa F, Paramio JM, Vara JAF, Castellano D.

Sci Rep. 2017 Nov 17;7(1):15819. doi: 10.1038/s41598-017-15920-6.

7.

Functional proteomics outlines the complexity of breast cancer molecular subtypes.

Gámez-Pozo A, Trilla-Fuertes L, Berges-Soria J, Selevsek N, López-Vacas R, Díaz-Almirón M, Nanni P, Arevalillo JM, Navarro H, Grossmann J, Gayá Moreno F, Gómez Rioja R, Prado-Vázquez G, Zapater-Moros A, Main P, Feliú J, Martínez Del Prado P, Zamora P, Ciruelos E, Espinosa E, Fresno Vara JÁ.

Sci Rep. 2017 Aug 30;7(1):10100. doi: 10.1038/s41598-017-10493-w.

8.

Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.

Gámez-Pozo A, Trilla-Fuertes L, Prado-Vázquez G, Chiva C, López-Vacas R, Nanni P, Berges-Soria J, Grossmann J, Díaz-Almirón M, Ciruelos E, Sabidó E, Espinosa E, Fresno Vara JÁ.

PLoS One. 2017 Jun 8;12(6):e0178296. doi: 10.1371/journal.pone.0178296. eCollection 2017.

9.

Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases.

Laimito KR, Gámez-Pozo A, Sepúlveda J, Manso L, López-Vacas R, Pascual T, Fresno Vara JA, Ciruelos E.

Ecancermedicalscience. 2016 Apr 11;10:632. doi: 10.3332/ecancer.2016.632. eCollection 2016. Review.

10.

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications.

Gámez-Pozo A, Berges-Soria J, Arevalillo JM, Nanni P, López-Vacas R, Navarro H, Grossmann J, Castaneda CA, Main P, Díaz-Almirón M, Espinosa E, Ciruelos E, Fresno Vara JÁ.

Cancer Res. 2015 Jun 1;75(11):2243-53. doi: 10.1158/0008-5472.CAN-14-1937. Epub 2015 Apr 16.

11.

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

Gámez-Pozo A, Pérez Carrión RM, Manso L, Crespo C, Mendiola C, López-Vacas R, Berges-Soria J, López IÁ, Margeli M, Calero JL, Farre XG, Santaballa A, Ciruelos EM, Afonso R, Lao J, Catalán G, Gallego JV, López JM, Bofill FJ, Borrego MR, Espinosa E, Vara JA, Zamora P.

PLoS One. 2014 Oct 20;9(10):e109611. doi: 10.1371/journal.pone.0109611. eCollection 2014.

12.

Shotgun proteomics of archival triple-negative breast cancer samples.

Gámez-Pozo A, Ferrer NI, Ciruelos E, López-Vacas R, Martínez FG, Espinosa E, Vara JÁ.

Proteomics Clin Appl. 2013 Apr;7(3-4):283-91. doi: 10.1002/prca.201200048. Epub 2013 Mar 6.

PMID:
23436753
13.

PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics.

Gámez-Pozo A, Sánchez-Navarro I, Calvo E, Agulló-Ortuño MT, López-Vacas R, Díaz E, Camafeita E, Nistal M, Madero R, Espinosa E, López JA, Fresno Vara JÁ.

PLoS One. 2012;7(3):e33752. doi: 10.1371/journal.pone.0033752. Epub 2012 Mar 26.

Supplemental Content

Loading ...
Support Center